Nearly 100,000 castrate-resistant prostate cancer patients in the United States and top five European markets have bone metastases, a condition that affects 90% of such patients, the company said.
Development plans for Alpharadin are continuing. Bayer and Algeta are already studying the drug in a phase II trial in breast cancer patients with bone metastases and have also initiated a trial evaluating the safety of Alpharadin in combination with chemotherapy in prostate cancer patients.
This coverage is provided courtesy of "The Pink Sheet." This news organization and "The Pink Sheet" are owned by Elsevier.